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Background: At the hospital level, decisions about purchasing new and oftentimes expensive medical
devices must take into account multiple criteria simultaneously. Multi-criteria decision analysis
(MCDA) is increasingly used for health technology assessment (HTA). One of the most successful
hospital-based HTA approaches is mini-HTA, of which a notable example is the Matrix4value model.
Objectives: To develop a funding decision-support tool combining MCDA and mini-HTA, based on
Matrix4value, suitable for medical devices for individual patient use in French university hospitals –
known as the IDA tool, short for ‘innovative device assessment’.
Methods: Criteria for assessing medical devices were identified from a literature review and a survey of
18 French university hospitals. Weights for the criteria, representing their relative importance, were
derived from a survey of 25 members of a medical devices committee using an elicitation technique
involving pairwise comparisons. As a test of its usefulness, the IDA tool was applied to two new drug-
eluting beads (DEBs) for transcatheter arterial chemoembolization.
Results: The IDA tool comprises five criteria and weights for each of two over-arching categories: risk and
value. The tool revealed that the two new DEBs conferred no additional value relative to DEBs currently
available.
Conclusions: Feedback from participating decision-makers about the IDA tool was very positive. The tool
could help to promote a more structured and transparent approach to HTA decision-making in French
university hospitals.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Health technology assessment (HTA) is increasingly performed
by health care agencies worldwide to support decision-making
concerning the uptake of new health technologies such as drug
therapies, equipment and medical devices. HTA, which is a multi-
disciplinary field bridging scientific evidence and policy-making
[1], considers a wide range of aspects, including medical, social,
ethical and economic implications of the development, diffusionand use of health technologies [2]. HTA has spread beyond just
national health care agencies; many hospitals have developed local
HTA models with respect to purchasing new and oftentimes
expensive health technologies [3].
One of the most successful hospital-based HTA approaches is
mini-HTA [4,5]. This decision tool is based on a checklist designed
for rapid assessment of four central aspects: technology, patient,
organization and economy. The key to the success of mini-HTA is
its capacity to integrate the views of end-users more effectively
into hospital policy actions, which has been identified as a decisive
factor in implementing hospital-based HTA [6,7].
Several authors have suggested that the future development of
HTA will necessarily incorporate multi-criteria decision
analysis (MCDA) [8–13]. MCDA is a methodology for helping
1 Co-invented by the second author (PH), the method and software is freely
available for academic and non-commercial use from him or via www.
1000minds.com.
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ering multiple criteria simultaneously [8]. Multi-attribute value
theory is the MCDA method most widely used in HTA, particularly
with respect to approaches based on additive models for aggregat-
ing alternatives’ performance across the multiple criteria [8]. A
wide range of techniques for eliciting decision-makers’ preferences
with respect to weights on the criteria, representing their relative
importance, is available [14–16].
Experiments testing approaches combining HTA and MCDA
have recently been performed, including the well-known
‘‘EVIDEM” project [17,18]. Approaches combining MCDA and
hospital-based HTA have also emerged, several of which use the
mini-HTA model – notably the Matrix4value model [5,19]. This
model comprises six criteria extracted from the mini-HTA form
for each of two over-arching categories: risk and value [5]. For each
of these categories, an overall score for each device under consid-
eration is produced by multiplying the expected performance score
on each criterion by its weight and then summing the weighted
part-scores. These two overall scores for each device can be
illustrated graphically in a similar fashion to a cost-effectiveness
quadrant, which can help decision-makers to discriminate, and
ultimately choose, between competing alternatives.
A tool combining MCDA and mini-HTA, such as Matrix4value,
could potentially improve hospital-based HTA activities in French
university hospitals by supporting a common, formal and transpar-
ent framework for evaluating new medical devices [20]. However,
earlier tools and methods have several important weaknesses.
First, as we pointed out in an earlier study [20], some of the
criteria within the mini-HTA model are unsuitable for medical
devices for individual patient use. This issue is important because
local HTAs in French hospitals do not necessarily involve the same
processes or stakeholders for medical devices with respect to
collective and individual patient use respectively [21]. Second,
the simple weight-elicitation technique used by Matrix4value
based on Likert scales has several drawbacks; for example, scales
have been shown to suffer from biases associated with decision-
makers not employing the scale’s full range to represent their pref-
erences [22]. These drawbacks could be remediated by using a
more robust methodology [17,22]. Finally, in order to encourage
medical device committees of French hospitals to adopt them,
methodologies need to be easy-to-use, cost-effective and repro-
ducible over time (which has not always been so in the past).
Thus, the objective of the study reported in this article is to
design and apply a mini-HTA/MCDA tool suitable for assessing
medical devices for individual patient use in French university
hospitals.
2. Methods
Consistent with most MCDA approaches in use internationally
[23] and based on the same rationale underpinning the develop-
ment of Matrix4value, we decided to build simple additive models
for the over-arching risk and value categories respectively. Such
‘compensatory’ models, where an alternative’s strengths on one cri-
terion can offset its weaknesses on one or more other criteria, have
been found to accurately reflect decision-makers’ preferences [24].
We followed a three-step approach to develop the mini-HTA/
MCDA tool – which we named IDA, short for ‘innovative device
assessment’. First, we selected relevant criteria for assessing new
medical devices for individual patient use based on a literature
review and a survey of 18 French university hospitals. We then
implemented a weight-elicitation technique that appropriately
balances methodological rigor and ease of use. Finally, as a test
of its usefulness, we applied the IDA tool under real-world condi-
tions in a university hospital by assessing two newmedical devices
relative to one currently available.2.1. Selecting decision criteria
We performed a literature review of mini-HTA-like models to
identify criteria considered in local HTAs for medical devices. We
also surveyed 18 French university hospitals to identify criteria
for assessing new medical devices. Details about the review and
survey are available in an earlier article [20].
The criteria identified from both sources were coded indepen-
dently by the first and sixth authors (NM and CD) and assigned
to one of the four mini-HTA perspectives mentioned earlier: tech-
nology, patient, organization and economy. Criteria that, in
essence, referred to the same concept were grouped under a com-
mon code; for example, ‘‘medical benefit”, ‘‘clinical benefit” and
‘‘health benefit” can be grouped together under the code ‘‘CLINICAL
BENEFIT”. Earlier studies of health decision criteria standardized
terms in a similar fashion [25].
We analyzed the criteria from both sources most frequently
considered for each mini-HTA perspective, and compared their
similarities and differences. Only criteria suitable for medical
devices for individual patient use were selected; for example, we
discarded criteria concerning devices’ physical-space impact. We
further reduced the number of criteria by retaining only those from
both the literature review and the survey. Finally, consistent with
conventional MCDA modelling guidelines, we did our best to
ensure that the criteria selected are complete, non-redundant,
operational and mutually independent [26].2.2. Determining criterion weights
As explained in the Introduction, our goal was to use a weight-
elicitation technique that is more methodologically robust than
relying on evaluation (e.g. Likert) scales while also being easy-to-
use, cost-effective and reproducible. After considering the wide
range of techniques available [23], often supported by specialized
software [27,28], we decided to use the PAPRIKA method [29]
implemented by 1000Minds software [30].1
As explained below, the PAPRIKA method – a partial acronym
for ‘Potentially All Pairwise RanKings of all possible Alternatives’
– is based on pairwise comparisons, and so it is less cognitively
burdensome for decision-makers than other methods. Another
advantage is that it yields a set of weights for each participant, in
contrast to other methods which produce aggregated data only,
thereby permitting us to compare weights across participant sub-
groups. Earlier applications of PAPRIKA and 1000Minds in the area
of health technology prioritisation include [31,32]; other health
applications include prioritising patients for elective surgery
[33,34], disease classification [35–37] and measuring clinical trial
outcomes [38–40].
The PAPRIKA method begins by identifying (performed by the
software) all pairs of, in the present context, hypothetical medical
devices defined on two criteria at-a-time and involving a trade-off.
Each participating decision-maker is repeatedly presented with
pairs of devices in random order and asked to choose which device
she prefers (has greater priority). An example of a pairwise-ranking
question appears in Fig. 1. Each time the decision-maker ranks a
pair of devices, all other hypothetical devices that can be pairwise
ranked via transitivity are identified and eliminated; for example,
if a decision-maker prefers device X over Y and then she prefers
Y over Z, then – by transitivity – X is also prioritised over Z (and
so the method would not ask a question relating to this third pair
of devices).
Fig. 1. Example of a pairwise-ranking question (a screenshot from 1000Minds software).
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number of questions a decision-maker is asked is minimized (as
reported in the next section, on average, 18 questions per person);
and yet the decision-maker ends up having pairwise ranked all
hypothetical devices differentiated on two criteria at-a-time, either
explicitly or implicitly (by transitivity). Finally, from the decision-
maker’s explicit pairwise rankings, the software uses mathematical
methods based on linear programming to derive weights for the
criteria (for technical details, see [29]). These weights are reported
at the individual decision-maker level and also averaged across the
group of participants.
The overall scores for risk and value respectively are calculated
using Eqs. (1) and (2) below. Thus, for each device j, multiplying
the mean weights Wi for each criterion i (normalized across the
10 criteria so the weights sum to one) by the performance scores
for the risk- and value-based criteria respectively, Ri,j and Vi,j, gives
overall scores for risk and value, SRj and SVj.
SRj ¼
X5
i¼1
Wi  Rij ð1Þ
SVj ¼
X5
i¼1
Wi  Vij ð2Þ2.3. Applying the IDA tool
To test the usefulness of the IDA tool, we worked with the med-
ical devices committee Comité des dispositifs médicaux stériles
(CODIMS) of the association Assistance Publique-Hôpitaux de Paris
(AP-HP), which represents all 38 university hospitals in Paris and
is the largest health care provider in France, to apply the tool.
CODIMS is responsible for reviewing the evidence to make
recommendations on technologies’ proper and for deciding which
medical devices should be adopted by the AP-HP network [41].
CODIMS’s scientific secretariat is responsible for performing
HTAs, which are based on local data and involve comparisons of
new devices vis-a-vis devices currently available in the AP-HP net-
work. Based on this evidence, CODIMS’s committee of representa-
tives, comprising 25 permanent members (14 medical doctors and
11 hospital pharmacists) and also other invited members, makes
recommendations about the adoption of new devices by the
network.
We applied the IDA tool in an evaluation of two new drug-
eluting beads (DEBs) for transcatheter arterial chemoembolization,
a treatment for hepatocellular carcinoma. Although DEBs are
already funded in the AP-HP network, interventional radiologistshad expressed interest in two new DEBs that recently became
available. They requested a HTA from CODIMS, asking in particular
whether the purchase of these new DEBs could extend the clinical
indications for using DEBs. A systematic review of the literature
performed by the scientific secretariat did not find any clinical
studies directly comparing the DEBs.
The 25 permanent members of CODIMS were invited to partic-
ipate in an online pairwise-ranking survey administered by the
1000Minds software discussed earlier. As well as generating mean
criterion weights for the IDA tool, weights at the individual-
participant level enabled us to compare weights from medical
doctors versus hospital pharmacists (as mentioned earlier, both
groups are members of CODIMS). This comparison was performed
via a Mann-Whitney U test, using R software, version 2.14.1 [42].
Based on the scientific secretariat’s HTA report on the two new
DEBs, two CODIMS hospital pharmacists – the fourth and fifth
authors (AB and ALC) – and an independent researcher – the first
author (NM) – independently rated the two new DEBs, DEBA and
DEBB, on the 10 decision criteria relative to DEBs currently in
use, DEB0. For DEBA and DEBB respectively, a score for each
criterion was assigned, which could take three possible values:
‘‘1” for a higher performance (i.e. relative to DEB0), ‘‘0” for the same
performance or it is not possible to reach a conclusion, or ‘‘1” for
a lower performance. If the three scorers were not unanimous in
their ratings, the disagreement was discussed until a consensus
score was agreed to.
Finally, applying Eqs. (1) and (2) above, the consensus scores for
DEBA and DEBB were multiplied by the corresponding criterion
weights and summed to produce overall scores for the risk and
value categories respectively. These overall values were plotted
on a graph with ‘‘value” on the horizontal axis and ‘‘risk” on the
vertical axis using Microsoft Office Excel 2010 [43]. To illustrate
the degree of uncertainty of the scoring process and to provide a
visual sensitivity analysis for the CODIMS committee of represen-
tatives, this graph also included overall scores arising from the
three individual scorers.3. Results
3.1. Decision criteria
Upon completion of the two-step selection procedure, 26 crite-
ria were initially identified, as reported in Table 1. Ensuring as
much as possible that the criteria are complete, non-redundant,
operational and mutually independent (see Table 1 again) necessi-
tated the culling of more than half of these initial criteria, leaving
Table 1
26 evaluation criteria identified in the literature review and survey of French university hospitals.
Perspective Evaluation criteria identified
(code)
Definition Mutual
independence
Operationality Decision criteria selected
(code)
Economy ECOREVIEW Review of economic evaluation studies U
UNITCOST Unit cost of the device U U UNITCOST
COST PER PATIENT Cost per patient excluding the unit cost of the device U U COST PER PATIENT
BUDGETIMP Budgetary impact of the adoption of the device U
DRGTARIFF DRG tariff including device cost U U DRGTARIFF
ADDPAYMENT Additional payment for the device U U ADDPAYMENT
Organization PATIENTNB Number of patients treated with the device per year U U PATIENTNB
EXPERTISE Need for specific expertise in the users U U EXPERTISE
TRAINING Need for user training U U TRAINING
ADDMD Need for additional medical devices to use with the
new device
U
WORKFLOW Impact on work flow within the hospital U U WORKFLOW
Patient CONFLINT Conflict of interest U
QUALITYOFLIFE Impact on patient quality of life U U QUALITYOFLIFE
Technology CURRENTHT Description of the currently available technology U
REVIEW Review of clinical evaluation studies U
CLINICAL BENEFIT Expected health gains for the patient U U CLINICAL BENEFIT
DESCRIPTION Description of the new device U
OTHERHOSP Adoption of the device at other hospitals U
PREVIOUS USE Previous uses of the device within the hospital (e.g.
clinical trials)
U
SAFETY Expected risks and/or adverse events related to the
device
U U SAFETY
INDICATION Indications for the device U
INNOVATIVENESS Novelty of the device U
EVIDENCE Quality of evidence on the device U U EVIDENCE
OPINION Opinions from a HTA agency or scientific society
about the device
U U OPINION
STUDY Ongoing studies on the device U
TYPE Type of device (diagnosis, treatment. . .) U
DRG: diagnosis-related group; HTA: health technology assessment
Table 2
Decision criteria included in the IDA tool.
Decision criterion Definition
Risk-based criteria
TRAINEXP Need for specific expertise and/or training of users
WORKPAT Number of patients and impact on work flow within the
hospital
COST PER PATIENT Cost per patient excluding the unit cost of the device
COVERAGE DRG tariff or additional payments for the device
UNIT COST Unit cost of the device
Value-based criteria
SAFETY Expected risks and/or adverse events related to the
device
CLINICAL BENEFIT Expected health gains for the patient
QUALITY OF LIFE Impact on patient quality of life
OPINION Opinion of a HTA agency or scientific society concerning
the device
EVIDENCE Quality of the evidence concerning the device
DRG: diagnosis-related group; HTA: health technology assessment.
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category. In order to match the numbers of risk-based and value-
based criteria (five each) two pairs of criteria in the risk category
were combined to generate two composite criteria. The final five
criteria in each category are reported in Table 2.
3.2. Criterion weights
In the four weeks before the triannual CODIMS meeting in June
2014, all 25 permanent members of CODIMS completed the online
pairwise-ranking survey. Each participant was required to answer
18 pairwise-ranking questions on average, typically taking
5–10 min in total per person. The mean criterion weights arepresented in Fig. 2. It can be seen that the mean weights for the
value-based criteria are very similar to each other: in the 12–15%
range. The mean weights for the risk-based criteria are lower: in
the 4–8% range. There are no statistically-significant differences
between medical doctors and hospital pharmacists with respect
to their weights (p > 0.05).3.3. Application of the IDA tool
The scoring scale used by the three scorers to independently
rate the performance of the two new DEBs (DEBA and DEBB) on
the 10 decision criteria relative to DEBs currently in use (DEB0) is
explained in Table 3. The scorers’ ratings, a consensus rating and
the overall scores on the risk- and value-based criteria respectively
are reported in Table 4.
According to the IDA tool, as represented in Fig. 3, DEBA delivers
the same amount of value and slightly less risk than DEB0, whereas
DEBB is less valuable and more risky than DEB0. Clearly, DEBB is
dominated by the DEBs currently available, and so the committee
of representatives rejected it. After deliberating, the committee
rejected DEBA too – because the committee considered it did not
offer new therapeutic options and the risk reduction was negligible
(relative to DEBs currently available).4. Discussion
In the hospital context, multiple criteria must be considered
simultaneously when deciding whether or not to adopt new med-
ical devices, and the analytical framework needs to be structured
and transparent about how decisions are reached; this is an advan-
tage of MCDA over traditional decision-making processes [12].
Based on the concept of mini-HTA and applying relevant decision
15%
13%
13%
13%
12%
8%
7%
7%
6%
4%
0%
2%
4%
6%
8%
10%
12%
14%
16%
SAFETY
QUALITY OF LIFE
CLINICAL BENEFIT
EVIDENCE
OPINION
COST PER PATIENT
WORKPAT
COVERAGE
UNIT COST
TRAINEXP
Mean
Fig. 2. Radar chart of the mean criterion weights for the 25 CODIMS members.
TRAINEXP: need for specific expertise and/or training of users; WORKPAT: number
of patients and impact on work flow within the hospital; COST PER PATIENT: cost
per patient excluding the unit cost of the device.
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the Matrix4value model, we developed the IDA (‘innovative device
assessment’) decision-support tool. This combination of MCDA and
HTA seems to result in fairness of the priority-setting process, an
essential condition for an ethical HTA framework: accountability
for reasonableness [17,24,44].
We used the PAPRIKAmethod implemented by 1000Minds soft-
ware to elicit decision-makers’ preferences with respect to weights
on the criteria, representing their relative importance. This method
proved easy to implement and was judged to be highly satisfactory
by all participants. PAPRIKA’s defining characteristic is that it is
based on answering pairwise-ranking questions (see Fig. 1 again),
which has the advantage that pairwise ranking – choosing one
alternative (here, medical devices) from two – is a natural typeTable 3
Comparative scoring scale used in the IDA tool.
Decision criterion Score
1 0
Risk-based criteria
TRAINEXP Less expertise or training required
than for the device currently
available
The same perform
possible to draw a
WORKPAT Lower impact on the number of
patients and on work flows than for
the device currently available
COST PER PATIENTa Cost per patient treated lower than
for the device currently available
COVERAGE Better coverage than for the device
currently available
UNITCOST Unit cost of the device lower than for
the device currently available
Value-based criteria
SAFETY Less secure than the device currently
available
The same perform
possible to draw a
CLINICAL BENEFIT Lower clinical benefits than for the
device currently available
QUALITY OF LIFE Lower impact on patient quality of
life than the device currently
available
OPINION Negative opinion about the device
from a HTA agency or scientific
society
EVIDENCE Less high-quality evidence than for
the device currently available
a Cost per patient excluding the unit cost of the device.of decision activity that everyone has experience of in their daily
lives. As Drummond et al. [45] argue in support of such methods
in general: ‘‘The advantage of choice-based methods is that choos-
ing . . . is a natural human task at which we all have considerable
experience, and furthermore it is observable and verifiable.”
In contrast, most other weight-elicitation techniques, of which a
well-known example is the analytical hierarchy process (AHP) [46],
are based on ‘scaling’ or ‘ratio’ measurements of decision-makers’
preferences. We preferred PAPRIKA over AHP because AHP is based
on asking decision-makers to express ratio-scale measurements of
their preferences – e.g. ‘‘On a 1–9 scale, how much more or less is
one criterion (or alternative) preferred to another?” – which is cog-
nitively demanding relative to PAPRIKA’s simple ordinal (ranking)
measurements, as discussed above.
A potential limitation of techniques based on pairwise ranking,
such as PAPRIKA, is the relatively large number of comparisons
required which may be excessively burdensome for decision-
makers. However, in this study no participantsmade any comments
concerning the time required to complete the pairwise-ranking
survey (typically 5–10 min per person and involving 18 pairwise-
ranking questions on average). On the contrary, the feedback
obtained was very positive with most participants finding the
survey to be user-friendly and simple, as in other applications of
1000Minds software [47].
The EVIDEM team recently suggested that weight-elicitation
techniques based on pairwise comparisons (as for PAPRIKA) are
likely to offer better discrimination with respect to the weight esti-
mates produced than other methods [47]. Indeed, we observed that
the participants in our pairwise-ranking survey gave more weight
to value-based criteria than to risk-based ones. The Matrix4value
study, whose weight-elicitation technique was based on Likert
scales, reported similar findings, but with more homogeneous
results both within and between the two over-arching value and
risk categories [5]. We speculate that Matrix4value’s poor discrim-
ination was due to the inferior weight-elicitation technique used.1
ance, or not
conclusion
More expertise or training required than for the device
currently available
Higher impact on the number of patients and on work
flow than for the device currently available
Cost per patient treated higher than for the device
currently available
Poorer coverage than for the device currently available
Unit cost of the device higher than for the device
currently available
ance, or not
conclusion
More secure than the device currently available
Greater clinical benefits than for the device currently
available
Greater impact on patient quality of life than the device
currently available
Positive opinion about the device from a HTA agency or
scientific society
More high-quality evidence than for the device currently
available
Table 4
Scores for the two new drug-eluting beads.
Decision criterion Scorer 1 Scorer 2 Scorer 3 Consensus score
DEBA DEBB DEBA DEBB DEBA DEBB DEBA DEBB
Risk-based criteria
TRAINEXP 1  0.04 1  0.04 1  0.04 1  0.04 0 0 1  0.04 1  0.04
WORKPAT 0 0 0 0 0 0 0 0
COST PER PATIENT 0 0 0 0 0 0 0 0
COVERAGE 0 0 0 0 0 0 0 0
UNITCOST 1  0.06 1  0.06 1  0.06 1  0.06 1  0.06 1  0.06 1  0.06 1  0.06
Overall score: Risk 0.02 0.10 0.02 0.02 0.06 0.06 0.02 0.10
Value-based criteria
SAFETY 0 0 0 0 0 0 0 0
CLINICAL BENEFIT 0 0 0 0 0 0 0 0
QUALITY OF LIFE 0 0 0 0 0 0 0 0
OPINION 0 0 0 0 0 0 0 0
EVIDENCE 0 1  0.13 0 1  0.13 1  0.13 1  0.13 0 1  0.13
Overall score: Value 0 0.13 0 0.13 0.13 0.13 0 0.13
DEBA: drug-eluting beads A; DEBB: drug-eluting beads B; TRAINEXP: need for specific expertise and/or training of users; WORKPAT: number of patients and impact on work
flow within the hospital; COST PER PATIENT: cost per patient excluding the unit cost of the device.
Criterion weights are shown in parentheses. Scores are assigned relative to the drug eluting-beads currently available in the hospital network: ‘‘1” for higher performance, ‘‘0”
for the same performance, or it is not possible to draw a conclusion, ‘‘1” for lower performance. The scores are multiplied by the corresponding criterion weights and
summed to yield an overall score.
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tation of the criteria’s relative importance.
In addition, the good discrimination of the PAPRIKA method
made it possible for us to compare weights between participating
hospital pharmacists and medical doctors, a potentially important
property in terms of the sustainability of the IDA tool. No statisti-
cally significant differences were observed, but this situation may
change over time as CODIMS’s members are replaced, and
monitoring of this aspect is therefore required.
The results obtained with the IDA tool, revealing that the two
new DEBs confer no additional value relative to DEBs currently
available, greatly assisted the CODIMS committee in its delibera-
tions. Careful identification of an appropriate comparator (i.e. the
device currently available) highlights the importance of defining
the scope of the HTA [2]. The motivation for the present HTA
was interventional radiologists’ interest in the potential added
value of the new DEBs being considered. Instead of asking whether
the new DEBs could be used to replace the device currently avail-
able, they focused on whether the new DEBs offered new therapeu-
tic possibilities. Before using the IDA tool, decision-makers should
clearly identify the over-arching question, including the counter-
factual, to be addressed.DEBB 1 
DEBB 2 
DEBB 3 
-16 -14 -12 -10 -8 -6 
VALUE
DEBB CS
DEBA 3 
Fig. 3. Comparison of the three drug-eluting beads based on the IDA tool results. DEBA: d
available. ‘‘1”, ‘‘2”, ‘‘3”represent the three scorers and ‘‘CS” the consensus score.Like all decision-support tools combining MCDA and HTA, the
results obtained depend on the quality of the underlying HTA
reports. The data evaluated must be reliable and comprehensive
in order for the new devices under consideration to be accurately
scored on the decision criteria without introducing judgment
biases. This is the main reason why we requested CODIMS’s
involvement in this study; CODIMS has a lot of expertise in
hospital-based HTA, ensuring that the IDA tool could be tested
under proper conditions [41].
Our findings highlight some of the prerequisites for the correct
implementation of the IDA tool in other French university hospi-
tals. Indeed, the IDA tool cannot be implemented alone because
it is intended to complement a well-conducted HTA process by
ensuring all important criteria are considered by decision-makers
in a more transparent manner. Consequently, the methodology
used for collecting and assessing evidence for medical devices
must respect good HTA practice to ensure that the evidence
submitted to decision-makers is of high quality. Nonetheless, some
criteria remained difficult to score despite rigorous adherence to
HTA guidelines. For example, quantifying the learning curve for
the new medical device is important when considering organiza-
tional impacts, such as expertise and training [48]; unfortunately,-4 
-2 
0 
2 
4 
6 
8 
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12
-4 -2 0 2 4 
DEB0 
DEBA CS
RISK
DEBA 1&2
rug-eluting beads A; DEBB: drug-eluting beads B; DEB0: drug-eluting beads currently
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often very poor [49]. In general, high quality clinical data for med-
ical devices are rarely available due to methodological difficulties
associated with designing trials (mainly involving randomization
and blinding). Consequently, studies available for recently mar-
keted devices are mostly case series and not often large compara-
tive studies or randomized controlled studies.
This study has several limitations worthy of discussion. First,
selection of the criteria was a relatively long and difficult process
due to the considerable variability of mini-HTA terminology. Two
researchers independently classified and coded the criteria, but this
process was limited by their subjective interpretations. Another
limitation concerned the testing of the IDA tool with CODIMS of
AP-HP (Assistance Publique-Hôpitaux de Paris), which is not
necessarily representative of all medical device committees across
France. We intend to carry out further tests in other university hos-
pitals to explore the tool’s strengths and weaknesses. As already
pointed out, themethodology used for collecting evidence is critical
to ensuring the correct scoring of the criteria. Nonetheless, check-
lists or scales are not always available or appropriate for capturing
the evidence for all criteria, and this is especially true for medical
devices. Indeed, we are often forced to use checklists originally
designed for medicines that do not closely match the specifications
of medical devices. Finally, the scoring was performed by three
scorers, but we believe that this step could be improved by involv-
ing the whole committee in the process, which would also improve
CODIMS members’ understanding of the process.
In conclusion, research on combinations of MCDA and hospital-
based HTA is in its infancy. Matrix4value opened up new possibil-
ities in this area, and we hope that this case study applying the IDA
tool helps to demonstrate the value of MCDA as a complement to
HTA at the hospital level. Before MCDA can be more widely used,
further studies would be useful to adapt and develop HTA in the
hospital context, as in the AdHopHTA project, for example [3].
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